combine drugs, devices, and/or biological products. The key aspect that determines how these products are regulated is their primary mode of action (PMOA). According to the FDA’s guidance, the PMOA dictates whether the product is classified as a drug, device, or biological product. This classification is fundamental as it informs the regulatory pathway that must be followed, hence compliance with extensive documentation, testing, and approval protocols.

Combination products may take several forms, such as:

• Drug-eluting stents (device coated with a therapeutic drug)
• Pre-filled syringes (device used to deliver a drug)
• Biologic products combined with a delivery device

The regulation of combination products involves the coordinated oversight of the FDA’s different centers—mainly the Center for Drug Evaluation and Research (CDER), the Center for Devices and Radiological Health (CDRH), and the Center for Biologics Evaluation and Research (CBER). Regulatory professionals in companies developing combination products should be familiar with the aspects of these centers’ regulations and guidance documents, especially when it comes to combination Good Manufacturing Practices (GMP).

Quality Systems for Combination Products

Quality management systems (QMS) are critical to ensuring compliance with manufacturing, safety, and efficacy standards across all regulated products. For combination products, manufacturers must adhere to the requirements set forth in regulations for both drugs and devices. The FDA articulates these requirements in various documents, including the Quality System Regulation (QSR) under 21 CFR Part 820 and the Current Good Manufacturing Practice (cGMP) regulations for drugs, outlined in 21 CFR Parts 210 and 211.

The following key elements are essential in establishing an effective quality system for combination products:

1. Quality Policy and Objectives

Establishing a clear quality policy is foundational. The policy should reflect the organization’s commitment to quality across all product lines and should define measurable objectives aligned with regulatory expectations.

2. Documentation Control

Develop and implement a documentation control system that ensures all procedures and records related to combination products are current, accessible, and adequately protected against unauthorized changes. This aligns with the FDA’s regulations found in 21 CFR Part 11 regarding electronic records.

3. Risk Management

Carrying out a risk management process that follows ISO 14971 is critical. The risks associated with combination products must be identified and mitigated throughout their lifecycle. This includes documenting risk analysis, evaluation, and control measures to address any potential hazards.

4. Design Controls

When developing combination products, manufacturers must enforce design control requirements, which include design planning, inputs, outputs, verification, validation, and design changes. The integration of these controls helps ensure that both the device and drug components of combination products work safely and effectively together.

5. Supplier and Contract Manufacturer Controls

Effective quality system management includes extensive oversight of suppliers and contract manufacturers. Manufacturers must verify the quality of components and services obtained from external sources, especially when these elements significantly impact the performance of the combination product.

Manufacturers are also required to assess and document the quality management systems of their suppliers in accordance with 21 CFR Part 820.50, relating to purchasing controls.

QSIT Inspection Model: An Overview

The Quality System Inspection Technique (QSIT) is an inspection approach utilized by the FDA to evaluate device manufacturers’ compliance with quality system regulations. The QSIT model focuses on four primary subsystems:

• Management Controls
• Design Controls
• Production and Process Controls
• Corrective and Preventive Actions (CAPA)

Understanding the requirements and expectations linked with each subsystem is crucial for regulatory, quality, and clinical professionals involved with combination products.

1. Management Controls

Management controls ensure that the organization has structured policies and procedures to implement an effective quality system. This includes establishing organizational structures and responsibilities, which ensure accountability for quality at all levels.

2. Design Controls

Compliance with design controls entails a robust framework for design and development processes, focusing on all product features, safety, effectiveness, and quality standards set forth for both device and drug components.

3. Production and Process Controls

This subsystem emphasizes the need for validated processes that ensure consistent manufacturing quality. Manufacturers must maintain stringent process controls, ensuring that they adhere to specifications and are capable of producing consistent and reliable end products.

4. Corrective and Preventive Actions (CAPA)

The CAPA system must be effective in identifying, investigating, and addressing non-conformance issues related to both drug and device components. A well-structured CAPA process facilitates continuous improvement, aligning with the FDA’s expectations for monitoring and maintaining post-market safety

Pivotal Role of OPQ and CDRH Coordination

Collaboration between the Office of Product Quality (OPQ) and the Center for Devices and Radiological Health (CDRH) is critical in the regulation of combination products. The OPQ is charged with overseeing the quality of drugs throughout their lifecycle, while the CDRH is responsible for the safety and effectiveness of devices.

This coordination is particularly vital during the development and approval phases, where combination products may face unique regulatory pathways due to their dual nature. Communication between these centers helps in addressing specific regulatory challenges associated with the PMOA and ensures comprehensive assessments of submissions for combination products.

Examples include the evaluation of labeling information which must comply with both drug and device regulations, and the premarket submissions to ensure the clinical data adequately reflects the safety and efficacy of all components involved.

Post-Market Safety Monitoring

Once combination products reach the market, adherence to post-market safety regulations is essential. The implementation of a robust post-market surveillance system is a regulatory requirement. In the event of adverse events, manufacturers are responsible for conducting thorough investigations and reporting them in compliance with 21 CFR Part 803.

Additionally, maintaining a continuous feedback loop through post-market studies and patient registries allows manufacturers to gather real-world evidence and insights, which are critical for ensuring ongoing product safety.

Conclusion

Understanding the regulatory requirements for combination products, particularly related to implementation of quality systems and the QSIT inspection model, is vital for professionals in the pharmaceutical and medical device industries. Compliance with the complex landscape of FDA regulations mandates a thorough approach, beginning with the development of a comprehensive quality management system and extending throughout the product lifecycle, including post-market obligations. By prioritizing these principles, manufacturers can ensure the successful development and continued safety of combination products designed to improve patient outcomes.

For more information on the regulations and guidelines related to combination products, refer to the FDA’s official documents and resources available on their website.